OraSure Technologies withdrew its FDA 510(k) and CLIA waiver submission for its InteliQuick CT/NG point-of-care molecular test after discussions with the agency, pushing clearance beyond the company’s targeted 2026 launch. The regulatory delay also changes economics tied to OraSure’s 2024 acquisition of Sherlock Biosciences, removing milestone-payment obligations that depended on FDA authorization.